Yazar "Şenel, Soner" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Delay between the onset of psoriasis and arthritis in PsA patients from the PsART international cohort(WILEY, 2019) Taşçılar, Koray; Aydın, Sibel Zehra; Akar, Servet; Aksu, Kenan; Bakırcı, Sibel; Bayındır, Ozun; Can, Meryem; Çetin, Gözde; Çınar, Muhammet; Dalkılıç, Ediz; Doğru, Atalay; Erden, Abdulsamet; Ersözlü, Emine Duygu; Erten, Şükran; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Küçükşahin, Orhan; Omma, Ahmet; Özişler, Cem; Şenel, Soner; Solmaz, Dilek; Tarhan, Emine Figen; Tinazzi, Ilaria; Yavuz, Şule; Yılmaz, Sema; Kalyoncu, Umut[Abstract not Available]Öğe The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia(TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY, 2019) Bilge, N. Şule Yaşar; Sarı, İsmail; Solmaz, Dilek; Şenel, Soner; Emmungil, Hakan; Kılıç, Levent; Oner, Sibel Yılmaz; Yıldız, Fatih; Yılmaz, Sedat; Bozkırlı, Duygu Ersözlü; Tufan, Müge Aydın; Yılmaz, Sema; Yazısız, Veli; Pehlivan, Yavuz; Bes, Cemal; Çetin, Gözde Yıldırım; Erten, Şükran; Gönüllü, Emel; Şahin, Fezan; Akar, Servet; Aksu, Kenan; Kalyoncu, Umut; Direskeneli, Haner; Erken, Eren; Kısacık, Bünyamin; Sayarlıoğlu, Mehmet; Çınar, Muhammed; Kaşifoğlu, TimuçinBackground/aim: The distribution of Mediterranean fever (MEFV) gene mutations in Turkish familial Mediterranean fever (FMF) patients varies according to geographic area of Turkey. There is a need for highly representative data for Turkish FMF patients. The aim of our study was to investigate the distribution of the common MEFV mutations in Turkish FMF patients in a nationwide, multicenter study. Materials and methods: Data of the 2246 FMF patients, from 15 adult rheumatology clinics located in different parts of the country, were evaluated retrospectively. The following mutations have been tested in all patients: M694V, M680I, M694I, V726A, and E148Q. Results: There were 1719 FMF patients with available genetic testing. According to the genotyping, homozygous M694V, present in 413 patients (24%), was the most common mutation . One hundred and fifty-four (9%) of patients had no detectable mutations. Allele frequencies of common mutations were: M694V (n = 1529, 44.5%), M680I (n = 423, 12.3%), V726A (n = 315, 9.2%), E148Q (n = 214, 1%), and M694I (n = 12, <1%). Conclusion: In this large-scale multicenter study, we provided information about the frequencies of common MEFV gene mutations obtained from adult Turkish IMF patients. Nearly half of the patients were carrying at least one M694V mutations in their alleles.Öğe Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia(DE GRUYTER OPEN LTD, 2015) Özaslan, Ersin; Eroğlu, Eray; Gök, Kevser; Şenel, Soner; Baldane, Süleyman; Akyol, Lütfi; Özkan, MetinyDrug induced lupus erythematosus (DILE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Platelet levels were increased and joint complaints disappeared in the first week of hydroxychloroquine and methylprednisolone treatment after chemotherapy had been discontinued. In conclusion, physicians should be alert to the possibility of DILE in patients presenting with thrombocytopenia under a capecitabine and bevacizumab chemotherapy regimen.Öğe The efficacy and safety of anti-tnf a treatment in ankylosing spondylitis patients with late onset compared to those with adult onset; the data from turkbio registry(BMJ PUBLISHING GROUP, 2019) Uslu, Sadettin; Can, Gerçek; Cefle, Ayşe; Yılmaz, Sema; Kocaer, Sinem Burcu; İnel, Tuba Yüce; Gülle, Semih; Koca, Süleyman Serdar; Yolbaş, Servet; Öztürk, Mehmet Akif; Şenel, Soner; İnanç, Nevsun; Dalkılıç, Ediz; Soysal, Özgül; Tufan, Abdurrahman; Akar, Servet; Birlik, Merih; Sarı, İsmail; Akkoç, Nurullah; Önen, Fatoş[Abstract not Available]Öğe Exon 2: Is it the good police in familial mediterranean fever?(AVES, 2019) Yaşar Bilge, Şule; Solmaz, Dilek; Şenel, Soner; Emmungil, Hakan; Kılıç, Levent; Öner, Sibel Yılmaz; Yıldız, Fatih; Yılmaz, Sedat; Ersözlü Bozkırlı, Duygu; Aydın Tufan, Müge; Yılmaz, Sema; Yazısız, Veli; Pehlivan, Yavuz; Beş, Cemal; Yıldırım Çetin, Gözde; Erten, Şükran; Gönüllü, Emel; Şahin, Fezan; Akar, Servet; Aksu, Kenan; Kalyoncu, Umut; Direskeneli, Haner; Erken, Eren; Kısacık, Bünyamın; Sayarlıoğlu, Mehmet; Çınar, Muhammed; Kaşifoğlu, Timuçin; Sarı, İsmailObjective: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Most of the identified disease-causing mutations are located on exon 10. As the number of studies about the effect of the exonal location of the mutation and its phenotypic expression is limited, we aimed to investigate whether the exonic location of the Mediterranean fever (MEFV) mutation has an effect on the clinical manifestation in patients with FMF. Methods: Study population was derived from the main FMF registry that included 2246 patients from 15 different rheumatology clinics. We categorized the mutations according to their exon locations and retrieved the clinical and demographic information from the database. Results: Patients having the MEFV mutations on exon 2 or 10 (n: 1526) were divided into three subgroups according to the location of the MEFV mutations: Group 1 (exon 2 mutations), Group 2 (exon 10 mutations), and Group 3 (both exon 2 and exon 10 mutations). Group 2 patients were of a significantly younger age at onset, and erysipel-like erythema, arthritis, amyloidosis, and a family history of FMF were more common in this group. Conclusion: Patients with FMF and exon 10 mutations show more severe clinical symptoms and outcome. Exon 2 mutations tend to have a better outcome.
